The Scientist

» business

Most Recent

image: Should Healthy People Have Their Exomes Sequenced?

Should Healthy People Have Their Exomes Sequenced?

By | March 24, 2017

With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

0 Comments

With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.

0 Comments

image: That Other CRISPR Patent Dispute

That Other CRISPR Patent Dispute

By | August 31, 2016

The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

1 Comment

Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.

0 Comments

image: Thermo Fisher to Acquire Affymetrix

Thermo Fisher to Acquire Affymetrix

By | January 11, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Biotech Stocks Take a Hit

Biotech Stocks Take a Hit

By | September 30, 2015

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

1 Comment

image: Treating Toxoplasmosis

Treating Toxoplasmosis

By | September 25, 2015

While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.

4 Comments

image: New Scripps Research Institute Leadership

New Scripps Research Institute Leadership

By | September 20, 2015

The nonprofit institution names a new CEO and president.

0 Comments

image: Biotech Buys Autoimmune Firm for $7B

Biotech Buys Autoimmune Firm for $7B

By | July 16, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Celladon Shutters Its R&D

Celladon Shutters Its R&D

By | June 26, 2015

Biotech firm likely to pull the plug after its gene therapy product fails.

0 Comments

Popular Now

  1. Antarctica Is Turning Green
  2. How to Tell a Person’s “Brain Age”
  3. Male Fish Borrows Egg to Clone Itself
  4. Life Science Funding Cuts Leaked
    The Nutshell Life Science Funding Cuts Leaked

    According to a document posted online less than a day before the release of the official 2018 budget proposal, the National Institutes of Health could face even deeper cuts than previously suggested by the Trump administration.

AAAS